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Summary 
 
Immunotherapy of malignancies aims at activating the patient’s own immune system 
to fight the tumour affecting the patient. Even though the use of dendritic cells (DC) 
has shown promising results, the DC vaccination strategy needs improvement, as only 
few relevant clinical responses could be documented so far. Aim: In this study, the 
standard protocol to generate monocyte derived DC using GM-CSF and IL-4 was 
compared to the use of GM-CSF and IL-15. Methods: Monocytes were isolated by 
plastic adherence from peripheral blood mononuclear cells and cultured for 6 days 
with GM-CSF and either IL-4 (IL4-DC) or IL-15 (IL15-DC). A fraction of the IL4-
DC was stimulated with a cytokine cocktail, while a fraction of the IL15-DC was 
stimulated by adding TNF-α 24 hours before harvesting. The phenotypes of the four 
DC populations were determined using flow cytometry. Intracellular signalling 
pathways were investigated using phospho-specific antibodies in a Western blot. IL-
12 production was analysed in an ELISA. Migratory capacity was determined in a 
chemotaxis assay. Results: Monocytes cultured with GM-CSF and IL-15 developed a 
DC-like morphology. Phenotypic analyses revealed that both IL4-DC and IL15-DC 
had down-regulated CD14 expression and up-regulated CD1a expression, although 
IL15-DC to a lesser extent. IL15-DC showed an enhanced surface expression of co-
stimulatory molecules CD80 and CD86 whereas no difference was observed in 
surface expression of MHC class II and CD40. Upon stimulation, an up-regulation of 
the maturation marker CD83 and CD86 were observed on IL4-DC only. The IL15-DC 
had more phosphorylated JNK and ERK than IL4-DC whereas the phosphorylation 
level of p38 in both IL4-DC and IL15-DC were approximately the same. None of the 
cell populations produced IL-12 or showed chemotaxis towards CCL19. 
Conclusions: The generation of IL15-DC turned out to be more problematic 
compared to the generation of IL4-DC. The stimulatory activity of IL-15 on T-cell 
proliferation resulted in a high degree of contamination with T -cells in the IL15-DC 
cultures as I did not have a pure monocyte population to start with. This problem 
might be overcome by using either alternative monocyte isolation protocols or by 
reducing the culture period from 5-6 to 3-4 days. Because of the variation in the 
results of the experiments the data needs to be confirmed with this approach.  
                                                                                                                        IL15-DC                                                                                           
 2 
Abbreviations 
 
Abbreviation  Name Abbreviation Name 
Ag Antigen LC Langerhans cells 
APC 
 
Antigen presenting cells LPS Lipopolysaccharide 
APS Ammonium persulfate mAb Monoclonal antibody 
BSA Bovine serum albumin MHC Major 
histocompatibility 
complex 
CFDA SE Carboxyfluorescein 
diacetate succinimidyl ester 
MLR Mixed leukocyte 
reaction 
CFSE Carboxyfluorescein 
succinimidyl ester 
NAC Non adherent cells 
CTL Cytotoxic T-lymphocytes NK Natural killer  
DC 
 
Dendritic cells 
 
NKT Natural killer T-cells 
dH2O Distilled water PAMP Pathogen associated 
molecular patterns 
DMSO Dimethyl sulfoxide RT Room temperature 
EDTA Ethylenediaminetetraacetic 
acid 
SDS 
 
 
Sodium dodecyl Sulfate 
 
FBS 
 
Fetal bovine serum 
 
SSC Side scatter channel 
FSC Forward scatter channel TCR T-cell receptors  
GM-CSF 
 
Granulocyte macrophage 
colony stimulating factor 
TH cells T helper cells 
IFN-γ Interferon gamma TLR Toll-like receptors 
IL Interleukin TNF Tumour necrosis factor 
IL-1β Interleukin 1 beta TSLP 
 
Thymic stromal 
lymphopoietin 
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1. Introduction 
1.1 Immune system 
 
The human body is always exposed to pathogenic infectious agents and, yet, the body 
usually can resist the invasion of these agents. It is our immune system that protects 
us against these infectious agents. The immune system has two main branches, innate 
or non-specific immune system and adaptive or specific immune system. Vertebrates 
are the only organism having an adaptive immune system. The main function of the 
immune system is to distinguish between self and non-self antigen, which is a vital 
step in protecting our body from invading microbes or/and elimination of altered cells, 
e.g. tumour cells.  
 
1.1.1 Innate immunity  
 
Innate immunity is the first line of the host immune defence. In fact, innate immunity 
can eliminate and prevent infections of the host as well as initiate adaptive immune 
responses. The innate immunity mechanism acts immediately and mounts a response 
against the antigen. However, the innate immune system does not generate lasting 
protective immunity (1).  
The principle components of the innate immunity are (i) the anatomic barrier, e.g. 
epithelia of the internal and external surfaces of the body, (ii) blood proteins, e.g. the 
complement system, (iii) cellular barrier, e.g. the phagocytes that can engulf and 
digest invading microorganisms, and (iv) cytokines which are proteins, peptides or 
glycoproteins. If the innate immunity for one reason or another fails to get rid of the 
infection, the response of the adaptive immune system takes place. 
The innate immunity lacks specificity, but recognises foreign pathogens as it 
identifies structures that are common to groups of related microbes. Therefore, cells 
of the innate immune system use a variety of pathogen-associated molecular patterns 
(PAMP) recognition receptors to recognise the patterns shared between pathogens. 
One of the major classes of the pattern recognition receptors are the Toll-like 
receptors (TLR).  
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The innate immunity also does not induce immunological memory and therefore each 
time the innate immune system acts against microbes as it would the first time.   
The principle effector cells of the innate immunity are neutrophils, macrophages, 
endothelial cells, dendritic cells and natural killer cells.  
 
1.1.2 Adaptive immunity 
 
The adaptive immunity is characterised by having the so-called immunological 
memory. This is a distinctive feature of the specific immune system and is defined as 
the ability to remember an encounter with a foreign antigen for a period of time or 
whole lifetime. This can help fight re-infection with the same microorganism. 
Another important feature of the adaptive immune system is its specificity as it has a 
diverse repertoire of rearranged receptors (2). The adaptive immune system depends 
on innate immune cells that are able to present antigens and this function is mainly 
controlled by antigen-presenting cells (APC). There are three different main types of 
professional APC, namely macrophages, B-cells and dendritic cells. The main cells of 
the adaptive immune system are T- and B-lymphocytes. T-lymphocytes arise from 
bone marrow and migrate to and mature in thymus, and they are the mediator of 
cellular immunity. On the other hand, B-lymphocytes arise and have their early stage 
of maturation in bone marrow and are the mediator of humoral immunity. B-
lymphocytes are the immune cells that produce antibodies.  
After naïve T- and B-lymphocytes emerge from the thymus and bone marrow, 
respectively, they migrate into the secondary lymphoid organs where they can be 
activated by different antigens presented to them and thereafter proliferate and 
differentiate into effector and memory cells. The effector cells include CD4+ helper T-
cells, CD8+ cytotoxic T-cells and antibody-secreting B-cells.  
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1.1.3 Dendritic cells 
 
Dendritic cells (DC) are the most potent antigen presenting cells that possess the 
ability to stimulate naïve T-cells. The DC capture antigens and process the antigens 
into peptides as they mature during their journey from the peripheral tissue to the 
lymphatic organs where the T-lymphocytes can recognise these peptides on the major 
histocompatibility complex (MHC) molecules which is important for the initiation of 
the immune response (3, 4). DC are critical for the induction of T-cell responses 
resulting in cell-mediated immunity. The term DC comes from the shape and motility 
that DC exhibit. These cells are mobile, stellate in shape (Figure. 1.1) and these 
features facilitate the cells’ function (5).   
 
 
 
 
Figure 1.1. Dendritic cell presenting antigen to a lymphocyte. The process involves intimate contact 
between the two cells in which DC projections might facilitate this function. Lymphocyte is stimulated 
by DC in order to proliferate and differentiate into effector cell. From: www.bcrfund.org/ 
images/dendriticcellb.jpg (accessed 5th April 2009) 
 
 
Few DC are required to stimulate the response of T-lymphocytes; it is estimated that 
one DC is able to stimulate 100-3000 T-lymphocytes (5).  
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1.1.3.1 DC subsets 
 
The different DC subsets are presented herein for just simplification of the issue, 
although, in real situation the picture is very complicated and a clear distinction is not 
always the case. DC precursors develop in the bone marrow and then home to a large 
variety of tissues. DC are present almost everywhere in the body, but mainly they 
reside in the peripheral tissue, the secondary lymphoid organs, and circulating in 
blood (6). All DC subsets originate from haematopoietic stem cells (HSC). DC are 
divided into subsets according to certain surface markers, these subsets have common 
features i.e. the DC morphology, expression of high amount of MHC class II and co-
stimulatory molecules as well as T-cell stimulation (7). Recent studies have 
characterised the DC subsets as belonging to the myeloid or lymphoid lineage (8). 
The myeloid DC contain subtypes including Langerhans cells (LC), which are located 
in the epidermis, interstitial DC, monocyte-derived DC and blood DC. The blood DC 
contain two subsets, mDC1 that is characterised by BDCA1 (CD1c) expression and 
mDC2 which are positive for BDCA3 (CD141) (9). The myeloid precursors also give 
rise to monocytes which in turn can differentiate into DC (10). Monocytes are not a 
major source of DC in vivo in the steady state. However, during infection the 
monocytes can differentiate into DC and they are called monocyte-derived DC. 
Finally, plasmacytoid DC are derived from the lymphoid lineage (8). These cells are 
remarkable in their ability to secrete large amounts of type I interferon (11). 
 
1.1.3.2 Antigen capturing, processing and presentation by DC 
 
DC are the sentinels of immune system and they are the link of the innate immunity to 
the adaptive immunity. The immature DC are present in the peripheral tissues where 
they can capture antigens, e.g. bacteria and virus. Immature DC use several pathways 
in order to capture antigens. These pathways are (i) macropinocytosis in which the 
cell membrane forms a pocket and pinches off into the cell to form a vesicle that 
travels into the cytosol and fuses with either endosomes or lysosomes and releases its 
content, (ii) receptor-mediated endocytosis through C-type lectin receptors or Fcγ 
receptor type I and II (12, 13), and (iii) phagocytosis in which the cell changes its 
Rania Al-Mahdi 
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shape by sending out projections which are called pseudopodia. These pseudopodia 
will surround the antigen and form an intracellular vesicle.    
When DC undergo the maturation process, the DC morphology will start to change. 
For example, the expression of receptors that are responsible for the phagocytic and 
endocytic process will be down-regulated (13). In addition, the co-stimulatory 
molecules CD40, CD80 and CD86 will be up-regulated, the MHC II compartment 
will start to change and the MHC class II-peptide complex will be translocated to the 
cell surface (14). Moreover, chemokine receptors, e.g. CCR7 that regulate DC 
trafficking will be up-regulated. Furthermore, the change of DC morphology will be 
associated with the secretion of chemokines that are responsible for the attraction of 
different effectors of the immune system as well as the secretion of cytokines such as 
IL-12 (15, 16). These maturation markers and the secretion of chemokines and 
cytokines will allow the optimal interaction between the DC and the T-cells.  
There are several factors that play a role in the induction and maturation of DC. These 
include (i) inflammatory cytokines e.g. tumour necrosis factor (TNF-α), interleukin 
(IL)-1, IL-6 and prostaglandin E2 (PGE2), (ii) pathogen-related molecules e.g. 
bacterial DNA, lipopolysaccharide (LPS) and double stranded RNA, (iii) antigen-
antibody complexes and (iv) the ligation of CD40 on DC by its ligand CD40L (13, 
17).  
The antigen that is captured by the immature DC will be processed and presented on 
the MHC molecules. Intracellular antigen that is in the cytosol of DC will bind to the 
MHC class Ι molecules and be presented to the CD8+ cytotoxic T-lymphocytes (CTL). 
However, antigens that have been captured and internalized into the endocytic 
pathway will bind to MHC class ΙI molecules and subsequently be presented to the 
CD4+T helper cells (TH). This in turn give help to other cells such as B-lymphocytes 
to start responding against these antigens (5, 18).  
When the DC present a peptide to a T-cell, the latter will induce a response called 
cellular immune response and that include both CD4+TH cells and CD8+ CTL (19). 
The T-cells need to recognise three signals in order to proliferate and differentiate into 
TH cells and CTL. The first signal in this process is the binding of MHC- peptide 
complexes to the T-cell receptors (TCR) and the second signal is the binding of the 
appropriate co-stimulatory receptor CD28 on the T-cells to the co-stimulatory ligands 
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CD80 or CD86 on the APC. A third signal delivered from the APC will determine the 
differentiation of T-cells into effector cells, e.g. the secretion of IL-12 from APC will 
differentiate the CD4+ T-cells into TH1 effector cells (Figure 1.2). The DC is not 
restricted to T-lymphocytes but can also activate B-lymphocytes (20, 21), natural 
killer (NK) cells (22), and natural killer T (NKT) cells (23). 
The immune system should recognise dangerous foreign antigens but should also be 
able to discriminate between self and non-self antigens to avoid autoimmunity. The 
DC are of critical importance in inducing T-cell tolerance. As it was mentioned above 
the T-cells need three signals in order to be activated, and if only signal 1 (binding of 
MHC- peptide complexes to the TCR) is delivered, this will cause T-cell inactivation 
leading to tolerance. Thus, DC have a great role in the contrast states of immunity and 
tolerance (5, 13). 
 
 
 
 
Figure 1.2. Three signals should be delivered from the DC in order to differentiate the T-cells 
into effector cells. Toll-like receptors (TLR) sense the presence of infection through recognition of 
PAMP (pathogen-associated molecular patterns). Recognition of PAMP by TLR expressed on DC will 
lead to the up-regulation of the MHC II molecules that present the antigenic peptide to the T-cells 
(signal 1) and the up-regulation of the co-stimulatory molecules CD80 and CD86 (signal 2). TLR also 
induce expression of cytokines, such as IL-12 (signal 3), and trigger many other events associated with 
DC maturation. All of the three signals lead to the activation of T-cells and the secretion of IL-12 
contributes to the differentiation of activated T-cells into T helper (TH)1 effector cells. From: Ruslan 
Medzhitov, 2001 (24). 
Rania Al-Mahdi 
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1.1.3.3 Ex-vivo generation of DC 
 
There are several sources from which we can generate DC ex vivo, e.g. from CD34+ 
haematopoietic progenitors or from monocytes isolated from blood. It is known that 
the combination of the cytokines granulocyte macrophage colony-stimulating factor 
(GM-CSF) with IL-4 will allow the differentiation of monocytes into DC (IL4-DC) 
and it is a standard protocol of ex-vivo generation of DC. In order to induce the IL4-
DC maturation, a cytokine cocktail composed of IL-6, TNF-α, IL-1β, and PGE2 is one 
of the acknowledged protocols and is regarded as a gold standard. (25). Finding the 
DC subset(s) that can make the optimal vaccines is a very critical step in order to 
improve DC-based vaccines. Much work has been done trying to test different 
cytokines or stimuli to the monocyte cultures in order to influence their differentiation 
ex vivo into DC with different phenotypes. For example, adding GM-CSF with IL-15 
to the monocytes will skew the differentiation of the monocytes into IL15-DC (Figure 
1.3) (26). Moreover, in the course of monocyte activation with, for example, GM-CSF, 
the monocytes can differentiate into different types of DC according to the different 
cytokines that will be added such as TNF (TNF-DC) (27), IFN-α (IFN-α-DC) (28) 
and thymic stromal lymphopoietin (TSLP-DC) (29) (Figure 1.3).  
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Figure 1.3. Subtypes of monocyte-derived DC. Activated monocytes with e.g. either GM-CSF, IL-3 
or FLT3L can differentiate into different DC subtypes after encounter with different cytokines such as 
IL-4 (IL4-DC), IL-15 (IL15-DC), TNF (TNF-DC), TSLP (TSLP-DC) and IFN-α (IFN-α-DC). These 
DC subtypes will differentiate the lymphocytes into immune effectors with different functions, leading 
to varied immune responses. From: Banchereau and Palucka, 2005 (30). 
 
 
1.1.4 Tumour immunology  
 
Cancer is a group of diseases that are characterised by the unregulated and 
uncontrolled cell proliferation. Altered cells arise on a regular basis but a vigilant 
immune system can eliminate them before they become harmful. Cells that evade 
immunosurveillance will develop into tumours, benign or malignant. Tumours vary in 
their immunogenicity, and even tumours with antigens that can be recognised by the 
host immune system can evade elimination. Cancer cells can use many mechanisms in 
order to evade T-cell responses, either to avoid being recognised by T-cells or trying 
to disable the effector T-cells (31). Moreover, the tumour may not display any danger 
signals that can activate the DC or other immune system components that be capable 
of acting against the tumour. 
An example of how the tumour cells avoid being recognised by T-cells, is the absence 
of MHC class I expression due to the mutations of the β2-microglobulin gene, or the 
down-regulation of MHC class I expression (32, 33). It was shown that many tumours 
progressed due to their suppression of the DC functions by IL-10, transforming 
growth factor-β (TGF-β) or vascular endothelial growth factor (VEGF) (34, 35). 
Another example is the signal transducer and activator of transcription (STAT) 3 that 
is activated in several tumour cases leading to the inhibition of DC maturation (36). 
Furthermore, the tumour microenvironment can induce immune tolerance as IL-10 is 
able to convert the DC function toward the induction of T-cell anergy (37).  
 
1.1.5 Immunotherapy  
 
Immunotherapy seeks to harness and enhance the patients’ own immune system 
against diseases including cancer. It is known that both chemotherapy and 
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radiotherapy usually lead to undesirable side effects and most of these side effects are 
the consequence of the cell damage brought by the chemotherapy agents or irradiation. 
These side effects constitute serious drawbacks of chemotherapy and radiotherapy. 
Initial studies using DC-based vaccinations have proven its safety and shown that it is 
well tolerated by patients. Certain cytokines and antibodies can be used as 
immunotherapy as well as vaccines. Transferring the immune effectors cells (T-cells) 
or proteins (antibodies) is called passive immunization, whereas active immunization 
is the ability to stimulate the patient’s own immune effector cells, e.g. DC-based 
vaccination (17). Vaccines intend to induce specific, non-toxic and long-lasting 
immune responses to prevent the infections and/or ameliorate the symptoms of the 
diseases vaccinated against (7). The same principle can be applied to vaccines against 
cancer. In the following section only immunotherapy concerning cancer will be 
discussed.  
Many studies were conducted and others are still going on after it had been shown in 
murine studies that the immune system can recognise and elicit potent anti-tumour 
immunity (38, 39). It is documented that ex-vivo generated DC that had been loaded 
with tumour antigens in mouse have the ability to induce protective (prophylactic 
vaccines) and therapeutic (therapeutic vaccines) anti-tumour immunity (40). It is 
shown also that the ex-vivo generated DC have the ability to induce therapeutic anti-
tumour immunity in humans (17). For the purpose of vaccination, the ex-vivo-
generated DC can be loaded or pulsed with specific tumour antigen(s) and then 
reintroduced back into the patient in order to stimulate the patient’s own immune 
system (Figure 1.4). 
To improve DC-based immunotherapy there are questions that need to be addressed. 
These are; the type of DC, the type of antigen(s) and their formulation, and the type of 
DC-activation signal as well as the route of injection (17). It was observed that 
distinct DC subsets would induce distinct types of immune response.  
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Figure 1.4. The principles of immunotherapy using DC-based vaccination. DC are generated from 
monocytes that were isolated from peripheral blood mononuclear cells. DC will then be loaded with 
specific tumour antigen followed by their injection to the patient in order to activate effector T-cells 
that can eliminate tumour cells. Modified from: 
www.ehealthandhealing.com/html/cancervaccines/cancervaccines.html. (accessed 20th April 2009) 
 
 
 
 
The route of injection is another important parameter that is unsolved and it is still 
unclear which route is optimal. Many injection routes have been tested, e.g. skin 
injections such as subcutaneous and intradermal injections, intravenous injections, 
injections into lymph nodes and intratumoural injections (41, 42). However, it has 
been shown that the subcutaneous injection is much less effective than intradermal 
and intranodal injections (43).  
It is known that a competent immune response is one that fulfils the following criteria 
(i) the ability to produce effector cells that are multifunctional, (ii) induce a broad 
range of effector cells that are specific for several types of tumour antigens, (iii) 
inhibit the tumour antigen-specific regulatory T-cell function and (iv) generate a 
tumour antigen-specific immune memory (17).  
DC-based vaccine taking into clinical trials and early studies showed that vaccines 
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using DC that were generated ex vivo from blood precursors result in a specific 
immune response in treating patients having tumour (44, 45). Recently, a phase III 
clinical trial also demonstrated a survival benefit in patients with metastatic hormone-
refractory prostate cancer treated with DC-based immunotherapy (46). In another 
randomized phase III trail, autologous peptide-loaded DC vaccination had to be 
prematurely closed. It was concluded that the DC-based vaccination was not more 
effective than DTIC chemotherapy in stage IV melanoma patients. However, they 
came out with future suggestions that might help for more effective vaccination (47).  
It has been observed that the outcomes of DC-based vaccination are variable. In many 
cases, a tumour-specific immune response was detected although the clinical benefit 
was limited (48, 49).  
Furthermore, an important factor that should be considered during the design of the 
DC-based vaccination is the ability of DC for migration. It was shown that less than 
1% of intradermally injected DC migrated rapidly to the regional lymphatics (50). In 
order to overcome this problem, previous studies tried to use different activation 
signals, e.g. PGE2 that can induce CCR7 expression; therefore increase the ability of 
DC to respond to CCL19 and CCL21 (51, 52). It is still a challenge to design vaccines 
that induce the optimal effective immune system by using DC-based vaccination, as 
the optimal type of DC that can be used for vaccination is not determined yet.  
                          
1.2 Aim of the study 
 
Immunotherapy of malignancies aims at activating the patient’s own immune system 
to fight the tumour affecting the patient. Even though the use of DC has shown 
promising results, the DC vaccination strategy needs improvement, as only few 
relevant clinical responses could be documented so far. In this study, the standard 
protocol to generate monocyte-derived DC using GM-CSF and IL-4 was compared to 
the use of GM-CSF and IL-15, which is thought to be better at inducing antigen-
specific cytotoxic T-lymphocyte differentiation in vivo.  
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2. Material  
 
2.1 Media and buffers 
 
Name Composition 
10x TBS 
 
1x Blotting buffer pH 8.3 
 
1x Running buffer 
 
 
0.1 M Tris pH 8.0 
1.4 M NaCl 
Running buffer without SDS 
20% Methanol 
0.1% SDS 
25 mM Tris 
192 mM Glycine 
1x TBST (0.5%) 
 
6x Lämmli buffer 
 
 
 
 
Blocking buffer 
 
FACS buffer 
PBS pH7.4 
1 x TBS 
0.5% Tween20 
375mM Tris HCl pH 6,8 
9 % SDS 
50% Glycerol 
9% β- Mercaptoethanol 
0,03% Bromphenolblue 
5% skimmed milk 
1x TBST (0.5%) 
0.5% BSA in PBS  
137mM NaCl 
2.7mM KCl  
 8.1mM Na2HPO4 
 1.5mM KH2PO4  
RIPA buffer 50 mM Tris pH7.4 
1% NP40 
0.25 % Sodium deoxycholate 
 150 mM NaCl 
 1mM EDTA 
 freshly added before use: 
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1X proteinase inhibitor complete ® 
1mM PMSF 
1mM Na-orthovanadate 
 1mM NaF 
RP10 RPMI 1640 with ultraglutamine 1 
 10% FBS 
50 units/ml Penicillin G sodium  
50 µg/ml streptomycin sulfate  
Stripping buffer 
 
 
Washing buffer 
2% SDS 
62.5 mM Tris/HCL pH 6.7 
100 mM β- Mercaptoethanol 
0.05% Tween-20 in PBS 
 
 
2.2 Cell culture plastic 
 
Name Company 
6-well plate Nunc, Denmark 
75cm2 flask Nunc, Denmark 
96-well plate Nunc, Denmark 
 
 
2.3 Softwares 
 
Name Company 
Flowjo Tree Star, Inc. 
Quantity one Bio-Rad, Hercules, California 
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2.4 Antibodies 
 
2.4.1 FACS antibodies 
 
Name                                         Clone Company 
CD14 FITC UCHM1 AbD Serotec, Oxford, UK 
CD1a PE NA1/34-HLK AbD Serotec, Oxford, UK 
CD38 APC 
CD4 APC 
AT13/5 
MEM-241 
AbD Serotec, Oxford, UK 
Immunotools, Germany 
CD40 FITC 
CD8 PE 
LOB7/6 
LT8 
AbD Serotec, Oxford, UK 
AbD Serotec, Oxford, UK 
CD80 APC MEM-233 Immunotools, Germany 
CD83 PE HB15e AbD Serotec, Oxford, UK 
CD86 FITC BU63 AbD Serotec, Oxford, UK 
CCR7 PE 150503 R&D system, USA 
HLA-DR APC HL-39 AbD Serotec, Oxford, UK 
 
2.4.2 Western blot antibodies 
Name                          Company 
AKT (Pan)(C67E7), Rabbit mAb                   Cell signalling, USA 
P38 MAP Kinase antibody 
P44/42 MAP Kinase, (137F5), Rabbit mAb 
 
phosho-AKT, (Ser473)(D9E), Rabbit mAb 
phosho-p38 MAPK, (Thr180/Tyr182), 
(3D7) Rabbit mAb 
Phospho-p44/42 MAP Kinase, 
(Thr202/tyr204), Rabbit mAb 
phospho- SAPK/JNK, (Thr183/Tyr185) 
 (81E11), Rabbit mAb 
SAPK/JNK, (56G8), Rabbit mAb 
 
Goat anti-rabbit (HRP) 
 
 
 
 
 
 
 
 
              
              Bio-Rad, Hercules, California      
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2.5 Reagents 
 
Name Company 
0.5M Tris-HCL buffer pH6.8 
1.5M Tris-HCL buffer pH8.8 
30%Acrylamide/Bis solution 
25x Proteinase inhibitor,complete EDTA free 
Albumin, bovine serum (BSA) 
Ammonium persulfate (APS) 
β-Mercaptoethanol 
CCL19 
Dimethyl sulfoxide (DMSO) 
Ethylenediaminetetraacetic acid (EDTA) 0.5M 
Glycine (Electrophoresis Purity Reagent) 
GM-CSF 
IL-1β 
IL-15 
IL-4 
IL-6 
Isopropanol prima 
Ionomycin 
Lymphoprep 
Pencillin/ strepotomycin  
PGE2 
Phorbol 12-myristate 13-acetate (PMA) 
Ponceau S 
Precision plus protein kaleidoscope standards                              
RPMI with Ultraglutamine 1 
Sodium dodecyl Sulfate (SDS) 
TNF-α  
Tris (Electrophoresis Purity Reagent) 
Tween20 
Bio-Rad, Hercules, California 
Bio-Rad, Hercules, California 
Bio-Rad, Hercules, California 
Roche, Germany 
Sigma, USA 
Bio-Rad, Hercules, California 
Sigma, USA 
Immunotools, Germany 
Sigma, UK 
Sigma, USA 
Bio-Rad, Hercules, California 
Immunotools, Germany 
Strathmann Biotec, Germany 
Immunotools, Germany 
Immunotools, Germany 
Immunotools, Germany 
Arcus, Oslo, Norway 
Sigma Aldrich, USA 
Axis- shield poc AS, Norway 
Invitrogen, USA 
Sigma Aldrich, USA 
Sigma Aldrich, USA 
Sigma Aldrich, USA 
Bio-Rad, Hercules, California 
BioWhttaker, Lonza, Belgium  
Bio-Rad, Hercules, California 
Immunotools, Germany 
Bio-Rad, Hercules, California 
Merck, Germany 
                                                                                                                        IL15-DC                                                                                           
 18 
2.6 Equipment 
 
Name Company 
Cabinet 
Cell counter CASY® 
Centrifuges 
 
 
ChemiDoc 
Flowcytometer, BDFACS Canto I 
Incubator 
Microscope 
Mini-PROTEAN 3 cell 
Mini-Trans-Blot Electrophoric Transfer 
Cell 
Nuair, biological safety cabinets  
Schärfe System GmbH, Germany 
- KUBOTA 8700, Tokyo, Japan 
- Thermo, Heraeus multifuge 1S-R, USA 
- Thermo, Heraeus Fresco 17, USA 
Bio-Rad, Hercules, California 
BD Biosciences, USA 
Forma Scientific, USA 
Leica, Germany 
Bio-Rad, Hercules, California 
Bio-Rad, Hercules, California 
 
Nitrocellulose trans-blot membrane 
(0.2µm 7x10 cm) 
Transwell® permeable supports 8 µm 
pore size 
Water bath 
Bio-Rad, Hercules, California 
 
Corning, NY, USA 
 
GFL, Germany 
 
2. 7 Kits 
 
Name        Company 
BCA protein Assay Kit     PIERCE, USA 
BD Compbeads 
CFSE (Vybrant™ CFDA SE, cell Tracer kit) 
    BD Biosciences, USA 
    Invitrogen, USA 
ELISA IL-12p70     BioLegend, USA 
Immuno-Star WesternC  Chemiluminescent 
kit 
    Bio-Rad, Hercules, California 
 
Materials that are not listed were either purchased from Bio-Rad, Sigma or Merck. 
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3. Methods 
 
3.1 Isolation of peripheral blood mononuclear cells (PBMC) from buffy coat 
 
Buffy coat was diluted ∼1:4 with phosphate buffered saline pH7.4 (PBS) at room 
temperature (RT). Approximately 33ml of the diluted buffy coat was carefully layered 
on top of 12ml lymphoprep. They were then centrifuged at 800g with no brake for 30 
minutes at 22°C. The PBMC were recovered from the plasma/lymphoprep interface 
and transferred into 50ml tubes. The PBMC were washed three times with cold PBS 
at 400g for 5 minutes at 4°C, suspended in RP10 medium and counted.  
 
3.2 Ex-vivo generation of different dendritic cell (DC) populations 
 
Dendritic cell generation started with the plating of 1x108 PBMC in a 75cm2 cell 
culture flask. Monocytes were isolated from PBMC by plastic adherence during the 
one-hour incubation at 37°C, 5% CO2 in humidified atmosphere while the 
lymphocytes remained floating. The non-adherent cells (NAC) were then transferred 
into a 50ml tube. The attached monocytes were washed with PBS (RT) 2-3 times until 
all floating cells were removed. To differentiate the monocytes into different DC 
populations, monocytes were cultured in new RP10 medium, 100 ng/ml of GM-CSF 
and either 20 ng/ml of IL-4 or 200 ng/ml of IL-15 to differentiate into IL4-DC or 
IL15-DC, respectively. The cells were then incubated for 5-6 days in a humidified 
atmosphere, 5% CO2, at 37°C. The cytokines were replenished every 2-3 days. 24 
hours before harvesting the cells a fraction of IL4-DC was matured by adding a 
cytokine cocktail consisting of IL-6 (1 x 103 IU/ml), IL-1β (10 ng/ml), TNF-α (10 
ng/ml) and PGE2 (1µg/ml) (CYTO-DC), whereas a fraction of IL15-DC was 
stimulated by 10 ng/ml of TNF-α (IL15+ TNFα-DC). 
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3.3 Freezing the cells 
 
To freeze the non-adherent cells, 90% of FBS and 10% of dimethyl sulfoxide 
(DMSO) were added to the cells. The solution should be aliquoted within 2-3 minutes, 
once the cells had come in contact with the DMSO. Approximately 5x107 cells/ml 
were frozen. The cell suspension was then transferred into cryo tubes which were 
placed into an isopropanol containing freezing container. The isopropanol containing 
freezing container was then stored at -80°C. This provides a relatively constant rate of 
freezing (-1°C \ min), thus improving viability.  
 
3.4 Cell counting 
 
Cell counting was done by using an automated cell counter (CASY), in which the cell 
suspension was diluted in casytone buffer. In addition, cell counting was done 
manually under the microscope using a Neubauer chamber, and the cell suspension 
was diluted in PBS and trypan blue.  
 
3.5 Harvesting cells  
 
After the incubation of monocytes for 6 days with the appropriate cytokines, the cells 
had developed into IL4-DC, IL15-DC, mature IL4-DC (CYTO-DC) and IL15+ TNF-
α-DC. To harvest each population, the cell suspension was transferred into 50ml 
tubes and centrifuged at 400g for 5 minutes at 4°C. Immediately PBS with 2mM 
EDTA was added to the flasks to harvest the remaining adherent cells. After 
centrifugation, the supernatant was transferred into cryo tubes to be stored at -20°C 
and the remaining cells in the PBS with 2mM EDTA were transferred to the obtained 
pellet. The tube was then centrifuged at 400g for 5 minutes at 4°C. The supernatant 
was discarded; PBS was added twice and centrifuged at 400g for 5 minutes at 4°C for 
the washing steps. DC were then counted.  
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3.6 Immunostaining for Flow cytometry 
 
To analyse the phenotype of the dendritic cell subsets, all DC populations were 
immunostained and analysed by flow cytometry. 
For each staining, 1x105 cells were resuspended in 50µl FACS buffer and 2µl of FcR 
block per 1x105 cells was added to block the Fc receptors. The surface markers that 
were detected by specific antibodies were: CD14, CD1a, HLA-DR, CD80, CD86, 
CD83, CD40, CCR7 and CD38. The IgG isotype controls included were labelled with 
FITC, PE and APC, and were used as a negative control. Compensation beads were 
used for the compensation control. The cells were then incubated in the dark for 10 
minutes at RT. After incubation the cells were washed twice with FACS buffer at 
400g for 5 min at 4°C. Finally, the cells were resuspended in 175µl of FACS buffer 
and transferred into FACS tubes and analysed on a FACS Canto flow cytometer 
within one hour.  
 
3.7 Chemotaxis 
 
During maturation of DC, some surface markers are up-regulated. CCR7 is a 
chemokine receptor up-regulated upon DC maturation that is a prerequisite for DC 
migration towards the CC-chemokine ligand CCL19. We tested the ability of the 
different DC subsets to migrate towards CCL19 by adding 5x104 DC to a 8-µm pore-
size transwell plate in 80µl of RP10 medium. Each DC subset was tested against 
CCL19, as well as against the RP10 medium alone. The lower compartment therefore 
contained 235µl of RP10 either with or without 100 ng/ml CCL19, respectively. The 
cells were incubated for 18 hours in a humidified atmosphere, 5% CO2 at 37°C. The 
migrated cells were then harvested from the lower chamber and counted using a 
CASY cell counter.  
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3.8 Mixed leukocyte reaction (MLR) 
 
3.8.1 Thawing and harvesting non-adherent cells (NAC) 
 
The NAC vial was thawed in 37°C water bath until a small lump of ice remained. 
NAC were added to 9ml warm RP10 and centrifuged at 400g, 5 minutes at room 
temperature before being washed again in RP10. The pellet was then dissolved in 5ml 
warm RP10 and transferred into a 25cm2 cell culture flask. The NAC were incubated 
at 37°C, 5% CO2 humidify atmosphere over night. NAC were harvested into a 50ml 
tube and centrifuged at 400g for 5 minutes at room temperature. The cells were 
resuspended in 10ml RP10 medium and counted. 
 
3.8.2 Labelling the NAC with Carboxyfluorescein succinimidyl ester (CFSE) 
 
The NAC were resuspend in warm PBS/0.1% BSA at a final concentration of 1x106 
NAC / ml and 1µl of a 10µM stock carboxyfluorescein diacetate, succinimidyl ester 
(CFDA SE) solution was added. The cells were then incubated for 10 minutes at 37°C. 
The CFDA SE will be converted by the cell into CFSE. The cells retain the CFSE in 
the cytoplasm and with each cell division the fluorescence intensity of the CFSE will 
decrease by half.  
To quench the reaction, 5 times of ice-cold RP10 medium was added before the cells 
were incubated on ice for 5 minutes. The labelled NAC were washed 3 times at 400 g 
for 5 minutes at 4°C with 20ml RP10. The labelled NAC were then counted. They 
were resuspended at a concentration of 2x106/ml RP10 medium.  
 
3.8.3 Co-culture of DC and allogenic NAC  
 
After harvesting, each DC population was added into a 96-well cell-culture plate in 
duplicate i.e. 8 wells in total. Each well contained 5x104 DC in 100µl RP10 medium. 
2x105 of allogenic CFSE labelled NAC were added only to one well of each DC 
subset. DC without NAC were used as a negative control to detect proliferation of 
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lymphocytes that originated from the DC culture. Moreover, three wells of labelled 
NAC were prepared as a negative control to detect lymphocytes proliferation that was 
independent from allogenic DC co-culture. In addition three wells with unlabelled 
NAC were prepared to be used later for compensation in the FACS analysis. 
Furthermore, one well of labelled NAC was stimulated with Phorbol 12-myristate 13-
acetate (PMA; 25ng) and Ionomycin (1µg) as a positive control. RP10 medium was 
added to a final volume of 200µl in each well. The NAC and DC were co-cultured for 
6 days. The cells were then harvested, washed and stained with CD4 APC and CD8 
PE antibodies. Thereafter, the cells were analysed by flow cytometry as described in 
3.6. 
 
3.9 Protein lysis 
 
After harvesting, the DC were washed once with PBS. The supernatants then were 
discarded; RIPA (Radio-Immunoprecipitation Assay) buffer was added to the cells 
(approximately 100µl of RIPA buffer per million cells). The protein lysates were then 
incubated on ice for 5-10 minutes. After the incubation the protein lysates were 
centrifuged at 17000g for 5 minutes at 4°C. Each supernatant was transferred into a 
new tube and a 5µl aliquot was taken for the BCA protein assay to determine the 
protein concentration. Both tubes were stored at -80°C until used in further analysis. 
 
3.10 BCA Protein Assay 
 
To determine the protein concentration of the protein lysates, we used the 
bicinchoninic acid (BCA) protein assay. The standard was prepared by making a two-
fold serial dilution of 1.5 mg/ml bovine serum albumin (BSA) into seven 1.5-ml tubes, 
and using the RIPA buffer as a blank. 10µl of each standard were transferred into a 
96-well plate in duplicates, and 10µl of RIPA buffer were transferred in duplicate as a 
blank.  
The protein lysate of each DC population was diluted 1:5 with PBS. Thereafter, 10µl 
from each sample were transferred into the 96-well plate in duplicate.  
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50 parts of BCA reagent A was mixed with 1 part of BCA reagent B to prepare the 
working reagent. After that, 200µl of the working reagent was added to each well of 
the standards and samples. It was then incubated at 37°C for 30 minutes. Finally, the 
absorbance was measured at 595nm on a plate reader and the sample’s protein 
concentration was calculated based on the standard. 
 
3.11 SDS-PAGE 
 
The main idea of sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) is to separate the proteins according to their size. Using SDS will denature the 
proteins as well as it will apply a negative charge in proportion to their mass. The 
proteins will move then through the gel according to their sizes toward the positive 
pole after an electrical field is applied.  
 
3.11.1 Gel preparation 
 
The gel was consisting of two types of gels, the resolving gel and the stacking gel. 
To make 2 minigels of resolving gel, 10ml of 12% resolving gel was prepared as 
follows: 
dH2O 3.4ml 
30% Acrylamide/Bis 4.0ml 
1.5M Tris-HCL pH 8.8 2.5ml 
10% SDS 100µl 
10% APS 50µl 
TEMED 5µl 
  
The solution was mixed well and was transferred to each glass cassette. The resolving 
gel was then layered with isopropanol to even the surface. The gel surface was rinsed 
after its polymerisation. The polymerisation took approximately 15-30 minutes.  
For the two minigels of stacking gel, 5ml of 5% stacking gel was prepared as follows: 
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dH2O 2.85ml 
30% Acrylamide/Bis 0.85ml 
0.5M Tris-HCL pH 6.8 1.25ml 
10% SDS 50µl 
10% APS 25µl 
TEMED 5µl 
 
The stacking gel solution was poured on top of the resolving gel and the comb was 
inserted carefully. The gel was left to polymerise between 15-30 minutes. 
 
3.11.2 Sample loading 
 
The samples were prepared by adding 6x Lämmli buffer to 20µg of protein lysate of 
each DC population and denaturing them at 100°C for 5 minutes. The marker and the 
samples were then loaded into the wells of the gel. The electrophoresis was run at 
150V for approximately 1:15 hours or until the blue running front had left the gel.  
 
3.12 Western blot 
 
After the proteins were separated by SDS-PAGE, the proteins were transferred to a 
nitrocellulose membrane. The proteins were transferred from the gel to the 
nitrocellulose membrane with a current of 250mA for one hour. The nitrocellulose 
membrane was then washed with 1xTBST (0.5%) and the proteins were visualised by 
incubating the membrane in a Ponceau S solution. The membrane was washed with 
1xTBST (0.5%) until we got rid of the Ponceau S solution colour. The nitrocellulose 
membrane was then soaked in the blocking buffer for one hour to block the non-
specific binding of proteins. The proteins were then detected one by one using 
specific primary antibody and secondary enzyme labelled antibody. The proteins that 
were detected are: AKT, ERK, JNK, P38 and their phosphorylated forms. All the 
primary antibodies were diluted 1:1000 in 5% BSA in 1xTBST (0.5%). The 
incubation time was for the phospho-proteins over night at 4°C. For the non-phospho 
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proteins, it was one hour at room temperature. After incubation, the nitrocellulose 
membrane was washed 5 minutes with 1xTBST (0.5%), 4 times. The secondary 
antibody goat anti-rabbit HRP was diluted 1:1000, added and incubated for 1 hour. 
The nitrocellulose membrane was then washed 5 minutes with 1xTBST (0.5%) and it 
was repeated for 4 times. The fifth time of washing was with 1xTBS. For the 
detection of proteins, Immuno-Star WesternC Chemiluminescent kit was used and the 
proteins were then analysed by ChemiDoc. The band intensity was measured for both 
the phospho and non-phospho forms of each protein that I detected in the four DC 
populations. CYTO-DC bands for both phospho and non-phospho forms of the 
proteins were set to 100%. The ratio between the phospho proteins and the non-
phospho proteins was then calculated. The ratio of the phospho to the non-phospho 
protein of CYTO-DC was therefore 1. Other DC populations were then compared to 
CYTO-DC. 
 
3.12.1 Stripping of the membrane  
 
The antibodies were removed from the membrane by stripping in order to allow 
detection of other proteins of interest with similar size. The membrane was incubated 
30 minutes in stripping buffer at 60°C with shaking followed by 5 times of 5 minutes 
each time of washing with 1xTBST (0.5%). The membrane was then blocked for 1 
hour before proceeding with the detection of another protein on the membrane.   
 
3.13 Enzyme-linked immunosorbent assay (ELISA) 
 
The amount of the cytokine IL-12p70 production for each DC population was 
analysed using a commercially available ELISA. A monoclonal anti-human IL-12p70 
antibody was first coated on a 96-well plate and incubated overnight at 2-8°C and the 
plate was then washed with the washing buffer 0.05% Tween-20 in PBS for 4 times. 
For blocking, Assay Diluent was added, and incubated at room temperature for 1 hour, 
after that the plate was washed with washing buffer for 4 times. The standard was 
prepared by making six two-fold serial dilutions of a 1000 pg/ml human recombinant 
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IL-12p70 solution. The conditioned medium from CYTO-DC, IL15-DC and 
IL15+TNF-α-DC were diluted 1:100. The standard, the diluted and undiluted samples 
were then added to the appropriate wells in duplicates and incubated at room 
temperature for 2 hours, followed by 4 times washing with washing buffer. The 
detection antibody biotinylated anti-human IL-12 p40/p70 was added to the wells and 
incubated at room temperature for 1 hour, followed by 4 times washing with washing 
buffer. Avidin-horseradish peroxidase (HRP) conjugate was added to the wells and 
incubated for 30 minutes. The plate was then washed 5 times, 1 minute per wash, with 
washing buffer. After that 3,3’,5,5’ - tetramethylbenzidine (TMB) substrate solution 
was added to each well, and incubated in the dark for 15 minutes to produce a blue 
colour in proportion to the amount of IL-12 p70 that is present in the samples. Finally 
the stop solution 1M H2SO4 was added to each well to change the reaction colour 
from blue to yellow and the absorbance was read at 450nm.  
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4. Results 
 
4.1 IL15-DC have the morphology of DC 
 
 
In order to see the influence of IL-15 on the differentiation of monocytes into DC and 
compare such effect to the standard protocol using IL-4, the monocytes were cultured 
in RP10 medium supplemented with GM-CSF together with either IL-4 (IL4-DC) or 
IL-15 (IL15-DC). A fraction of the IL4-DC was incubated with the cytokine cocktail 
IL-6, IL-1β, TNF-α and PGE2 for 24 hours (CYTO-DC). A fraction of IL15-DC was 
stimulated with TNF-α for 24 hours (IL15+TNFα-DC). All four cell populations had 
the morphology of DC after 6 days of culturing. However, the size of IL15-DC was 
smaller than IL4-DC and that was detected using the automated cell counter CASY 
and flow cytometry (Figure 4.1).     
 
 
 
 
Figure 4.1. IL15-DC have a smaller size than IL4-DC. Monocytes were cultured with GM-CSF and 
IL-4 (IL4-DC) or IL-15 (IL15-DC) for 6 days. The figure shows the forward scatter channel (FSC) and 
the side scatter channel (SSC) of the IL4-DC (left panel) and the IL15-DC (right panel). The FSC of 
the IL15-DC showed that the IL15-DC cells are smaller than the IL4-DC cells. Both IL15-DC and IL4-
DC had the same FSC and SSC setting. The data of one representative experiment is shown. DC were 
gated using FSC/SSC.  
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4.2 IL15-DC express less DC marker CD1a than IL4-DC  
 
IL15-DC expressed approximately the same level of the monocyte/macrophage 
surface marker CD14 as IL4-DC. However, the DC surface maker CD1a was 
expressed more in the IL4-DC. CYTO-DC expressed less CD14 but more CD1a 
comparing to IL15-DC. The stimulated IL15-DC with TNF-α expressed 
approximately the same levels of both CD14 and CD1a as IL15-DC (Figure 4.2).  
 
 
 
 
 
Figure 4.2. IL15-DC express less DC marker CD1a than IL4-DC. Monocytes were cultured with 
GM-CSF and IL-4 (IL4-DC) for 6 days, and 24 hours before harvesting, a fraction of IL4-DC was 
stimulated with the cytokine cocktail IL-6, IL-1β, TNF-α and PGE2 (CYTO-DC). Monocytes were 
cultured with GM-CSF and IL-15 (IL15-DC) for 6 days and a fraction of IL15-DC was stimulated for 
24 hours with TNF-α. The figure shows 3 independent experiments and the median is indicated by a 
bar. Flow cytometry was used to determine the percentage of cells that expressed CD14 (A) and CD1a 
(B). IL15-DC expressed similar level of monocyte/macrophage marker CD14 and less DC marker 
CD1a compared to IL4-DC. CYTO-DC expressed less CD14 but more CD1a compared to IL15-DC. 
The stimulated IL15-DC with TNF-α expressed approximately the same levels of both CD14 and 
CD1a as IL15-DC. 
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4.3 IL15-DC express more maturation markers than IL4-DC 
 
The DC maturation markers CD83 and HLA-DR were expressed more on IL15-DC 
than IL4-DC. The CYTO-DC expressed higher levels of CD83 and HLA-DR than the 
other populations. The stimulated IL15-DC with TNF-α expressed similar levels of 
CD83 and HLA-DR as IL15-DC (Figure 4.3). However, the median fluorescence 
intensity (MFI) of HLA-DR was higher on IL15-DC than the CYTO-DC and IL4-DC 
(Figure 4.4). 
 
 
 
 
 
Figure 4.3. IL15-DC express more maturation markers than IL4-DC. Monocytes were cultured 
with GM-CSF and IL-4 (IL4-DC) for 6 days, and 24 hours before harvesting, a fraction of IL4-DC was 
stimulated with the cytokine cocktail IL-6, IL-1β, TNF-α and PGE2 (CYTO-DC). Monocytes were 
cultured with GM-CSF and IL-15 (IL15-DC) for 6 days and a fraction of IL15-DC was stimulated for 
24 hours with TNF-α. The figure shows 3 independent experiments and the median is indicated by a 
bar. Flow cytometry was used to determine the percentage of cells that expressed HLA-DR (A) and 
CD83 (B). IL15-DC expressed more maturation surface markers HLA-DR and CD83 than IL4-DC. 
CYTO-DC showed more expression of the maturation surface markers HLA-DR and CD83 than the 
other populations. The stimulated IL15-DC with TNF-α expressed similar levels of HLA-DR and 
CD83 as IL15-DC. 
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Figure 4.4. The median fluorescence intensities of CD40 and HLA-DR are higher for IL15-DC 
than IL4-DC and CYTO-DC. Monocytes were cultured with GM-CSF and IL-4 (IL4-DC) for 6 days, 
and 24 hours before harvesting, a fraction of IL4-DC was stimulated with the cytokine cocktail IL-6, 
IL-1β, TNF-α and PGE2 (CYTO-DC). Monocytes were cultured with GM-CSF and IL-15 (IL15-DC) 
for 6 days and a fraction of IL15-DC was stimulated for 24 hours with TNF-α. The figure shows 3 
independent experiments and the median is indicated by a bar. Flow cytometry was used to determine 
the median fluorescence intensity (MFI) of HLA-DR (A) and CD40 (B). The MFI of HLA-DR and 
CD40 were higher on the IL15-DC than both the IL4-DC and the CYTO-DC. The MFI of CD40 and 
HLA-DR on the stimulated IL15-DC with TNF-α was approximately the same as IL15-DC. 
 
 
 
 
The co-stimulatory molecules CD86 and CD80 were expressed more on IL15-DC 
than IL4-DC. The CYTO-DC expressed higher level of CD86, whereas CD80 was 
expressed more on IL15-DC. Adding TNF-α to the IL15-DC resulted in the up-
regulation of CD86. The IL15-DC expressed more CD80 than the stimulated IL15-
DC with TNF-α (Figure 4.5). All DC populations expressed approximately the same 
level of the co-stimulatory molecule CD40 (Figure 4.5), but the MFI of CD40 was 
higher on IL15-DC than both IL4-DC and CYTO-DC (Figure 4.4). The MFI of CD40 
on the stimulated IL15-DC with TNF-α was approximately the same as on IL15-DC 
(Figure 4.4). 
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Figure 4.5. IL15-DC express more CD80 whereas CYTO-DC express more CD86. Monocytes 
were cultured with GM-CSF and IL-4 (IL4-DC) for 6 days, and 24 hours before harvesting, a fraction 
of IL4-DC was stimulated with the cytokine cocktail IL-6, IL-1β, TNF-α and PGE2 (CYTO-DC). 
Monocytes were cultured with GM-CSF and IL-15 (IL15-DC) for 6 days and a fraction of IL15-DC 
was stimulated for 24 hours with TNF-α. The figure shows 3 independent experiments and the median 
is indicated by a bar. Flow cytometry was used to determine the percentage of cells that expressed 
CD86 (A), CD80 (B) and CD40 (C). CYTO-DC expressed the highest level of the co-stimulatory 
molecule CD86. IL15-DC expressed more CD80 than IL4-DC and CYTO-DC. The stimulated IL15-
DC with TNF-α showed more CD86 and less CD80 expressions than IL15-DC. All DC populations 
showed approximately the same expression of the co-stimulatory molecule CD40.  
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4.4 CYTO-DC express more CCR7 whereas IL15-DC express more CD38 
 
The migration marker CCR7 was expressed more on the CYTO-DC than the other 
DC populations. IL15-DC expressed approximately the same level of CCR7 as the 
un-stimulated IL4-DC (Figure 4.6). IL15-DC showed the highest expression of the 
migration marker CD38. The addition of cytokine cocktail to the IL4-DC resulted in 
the down-regulation of CD38. The stimulated IL15-DC with TNF-α expressed 
approximately similar levels of CCR7 and CD38 as IL15-DC (Figure 4.6).  
 
 
 
 
Figure 4.6. CYTO-DC express more CCR7 whereas IL15-DC express more CD38. Monocytes 
were cultured with GM-CSF and IL-4 (IL4-DC) for 6 days, and 24 hours before harvesting, a fraction 
of IL4-DC was stimulated with the cytokine cocktail IL-6, IL-1β, TNF-α and PGE2 (CYTO-DC). 
Monocytes were cultured with GM-CSF and IL-15 (IL15-DC) for 6 days and a fraction of IL15-DC 
was stimulated for 24 hours with TNF-α. The figure shows 3 independent experiments and the median 
is indicated by a bar. Flow cytometry was used to determine the percentage of cells that expressed 
CCR7 (A) and CD38 (B). CYTO-DC showed the highest expression of CCR7, and both IL15-DC and 
IL4-DC had approximately the same level of CCR7 expression. IL15-DC showed the highest 
expression of CD38. Stimulated IL4-DC with cytokine cocktail showed down-regulation of CD38. The 
stimulated IL15-DC with TNF-α expressed approximately similar levels of CCR7 and the CD38 as 
IL15-DC. 
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4.5 Analyses of MAPK and AKT signalling pathways  
 
The intracellular MAPK signalling pathways involved in DC maturation were 
investigated using phospho-specific antibodies in a Western blot. The stimulated 
IL15-DC with TNF-α had more phosphorylated ERK 42/44 (P-ERK) than the other 
DC populations. However, IL15-DC had similar levels of P-ERK as CYTO-DC. IL4-
DC showed less P-ERK than all DC populations (Figure 4.7). All DC populations had 
approximately the same ratio of phosphorylated p-38 (P-p38) to p38 (Figure 4.8). 
 
 
 
 
Figure 4.7. IL15-DC shows a similar level of P-ERK like CYTO-DC. Monocytes were cultured with 
GM-CSF and IL-4 (IL4-DC) for 6 days, and 24 hours before harvesting, a fraction of IL4-DC was 
stimulated with the cytokine cocktail IL-6, IL-1β, TNF-α and PGE2 (CYTO-DC). Monocytes were 
cultured with GM-CSF and IL-15 (IL15-DC) for 6 days and a fraction of IL15-DC was stimulated for 
24 hours with TNF-α. The phosphorylation of the protein kinase ERK42/44 was analysed using 
Western blot. (A) shows representative bands of ERK and P-ERK for each DC population. (B) shows 
the results of 3 independent experiments and the median is indicated by a bar. The intensity of the 
bands was measured and CYTO-DC was set to 100%. The ratio of the phospho to the non-phospho 
protein was then calculated. The ratio of the phospho to the non-phospho ERK of CYTO-DC is 
therefore 1. IL4-DC, IL15-DC and stimulated IL15-DC with TNF-α were compared to CYTO-DC. 
IL15-DC showed similar levels of P-ERK as CYTO-DC. IL4-DC had less P-ERK than all DC 
populations. The stimulated IL15-DC with TNF-α had the highest level of P-ERK. 
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Figure 4.8. All DC populations have approximately the same ratio of phosphorylated p-38 to p38. 
Monocytes were cultured with GM-CSF and IL-4 (IL4-DC) for 6 days, and 24 hours before harvesting, 
a fraction of IL4-DC was stimulated with the cytokine cocktail IL-6, IL-1β, TNF-α and PGE2 (CYTO-
DC). Monocytes were cultured with GM-CSF and IL-15 (IL15-DC) for 6 days and a fraction of IL15-
DC was stimulated for 24 hours with TNF-α. The phosphorylation of the protein kinase p38 was 
analysed using Western blot. (A) shows representative bands of p38 and P-p38 for each DC population. 
(B) shows the results of 3 independent experiments and the median is indicated by a bar. The intensity 
of the bands was measured and CYTO-DC was set to 100%. The ratio of the phospho to the non-
phospho protein was then calculated. The ratio of the phospho to the non-phospho p38 of CYTO-DC is 
therefore 1. IL4-DC, IL15-DC and stimulated IL15-DC with TNF-α were compared to CYTO-DC.  
 
 
 
 
 
The CYTO-DC had more P-JNK 46/54 than the other DC populations. IL15-DC had 
more P-JNK 46/54 than the IL4-DC. However, the stimulated IL15-DC with TNF-α 
had less P-JNK 46/54 than IL15-DC (Figure 4.9). The AKT signalling pathway was 
also investigated using Western blot. However, phosphorylated AKT protein kinase 
was not detected in any of the DC populations (data not shown).  
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Figure 4.9. CYTO-DC have the highest level of phosphorylated JNK 46/54 (P-JNK). Monocytes 
were cultured with GM-CSF and IL-4 (IL4-DC) for 6 days, and 24 hours before harvesting, a fraction 
of IL4-DC was stimulated with the cytokine cocktail IL-6, IL-1β, TNF-α and PGE2 (CYTO-DC). 
Monocytes were cultured with GM-CSF and IL-15 (IL15-DC) for 6 days and a fraction of IL15-DC 
was stimulated for 24 hours with TNF-α. The phosphorylation of the protein kinase JNK 46/54 was 
analysed using Western blot. (A) shows representative bands of JNK 46/54 and P-JNK 46/54 for each 
DC population. (B and C) show the results of 3 independent experiments and the median is indicated 
by a bar. The intensity of the bands was measured and CYTO-DC was set to 100%. The ratio of the 
phospho to the non-phospho protein was then calculated. The ratio of the phospho to the non-phospho 
JNK 46/54 of CYTO-DC is therefore 1. IL4-DC, IL15-DC and stimulated IL15-DC with TNF-α were 
compared to CYTO-DC. The stimulated IL15-DC with TNF-α had a lower level of P-JNK 46/54 than 
IL15-DC. IL15-DC had more P-JNK 46/54 than IL4-DC.  
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4.6 IL-12p70 is not present in the cell culture supernatants of the four DC 
populations 
 
The cell culture supernatants of the four DC populations were analysed by ELISA for 
the presence of IL-12p70. There was no IL-12 detected in the cell culture supernatants 
of IL4-DC, IL15-DC, CYTO-DC and IL15-DC with TNF-α.  
 
4.7 No DC chemotaxis is detected in response to CCL19 
 
The ability of the four DC populations to migrate towards CCL19 was tested in order 
to determine whether the CCR7 is functioning. However, the four DC populations did 
not show any migratory ability towards CCL19.  
 
4.8 Lymphocytes co-cultured with CYTO-DC showed higher percentage of 
proliferation in a MLR 
 
To test the ability of DC to stimulate lymphocyte proliferation, a mixed leukocyte 
reaction (MLR) was set up. CFSE labelled allogenic lymphocytes (2×105) were co-
cultured with each DC population (5×104) for 6 days. CFSE is retained in the 
cytoplasm and with each round of cell division the fluorescence intensity of the CFSE 
will decrease by half. Lymphocytes that had been co-cultured with CYTO-DC 
showed the highest percentage of cell division as seen by reduction of CFSE positive 
cells. Lymphocytes that had been co-cultured with IL4-DC had a higher percentage of 
proliferation than both IL15-DC and the stimulated IL15-DC with TNF-α (Figure 
4.10). The lowest percentage of lymphocyte proliferation showed lymphocytes that 
had been co-cultured with the stimulated IL15-DC with TNF-α. For further analyses 
the CFSE labelled allogenic lymphocytes were stained with CD4 and CD8 antibodies. 
However, the cell counts were not high enough to be further analysed.  
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Figure 4.10. Lymphocytes co-cultured with CYTO-DC showed highest percentage of 
proliferation in a MLR. Monocytes were cultured with GM-CSF and IL-4 (IL4-DC) for 6 days, and 
24 hours before harvesting, a fraction of IL4-DC was stimulated with the cytokine cocktail IL-6, IL-1β, 
TNF-α and PGE2 (CYTO-DC). Monocytes were cultured with GM-CSF and IL-15 (IL15-DC) for 6 
days and a fraction of IL15-DC was stimulated for 24 hours with TNF-α. CFSE labelled allogenic 
lymphocytes (2×105) were co-cultured with each DC population (5×104) for 6 days. Flow cytometry 
was used to determine the percentage of lymphocyte proliferation. Lymphocytes were gated using 
FSC/SSC. The figure shows the percentage of lymphocyte proliferation after co-culturing allogenic 
lymphocytes with the indicated DC population. The negative control is CFSE labelled NAC without 
allogenic DC. Lymphocytes that had been co-cultured with IL4-DC had a higher percentage of 
proliferation than both IL15-DC and the stimulated IL15-DC with TNF-α. The lowest percentage of 
lymphocyte proliferation showed lymphocytes that had been co-cultured with the stimulated IL15-DC 
with TNF-α. 
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5. Discussion 
 
DC are the most potent antigen presenting cells that possess the ability to stimulate 
naïve T-cells. The DC maturation process represents a crucial step in the initiation of 
adaptive immune responses. DC maturation is accompanied by changes of their 
morphological, phenotypic, and functional properties. In order to clinically apply DC 
vaccine in cancer immunotherapy, choice of precursor cells, type of maturation 
stimuli involved in the development from immature to mature DC, and which DC 
subsets to be used, are yet to be optimised. 
In this study, I examined the phenotype, cytokine secretion, and T-cell stimulatory 
capacity of monocyte derived DC generated using GM-CSF and IL-15 (IL15-DC), 
and compared it to DC generated after the standard protocol using GM-CSF and IL-4 
(IL4-DC). 24 hours before harvesting, a fraction of IL15-DC was stimulated with 
TNF-α, while a fraction of IL4-DC was stimulated with a cytokine cocktail of IL-6, 
TNF-α, IL-1β and PGE2 (CYTO-DC). A previous study has shown that DC that were 
generated by using IL-15 were more efficient at T-cell induction as well as in priming 
cytotoxic T-lymphocytes, a process that may help to overcome the tumour escape 
mechanisms (53). However, in that study, LPS was used for stimulation. LPS is a 
good stimulant for the DC but it is questionable to put back DC that might have 
residual LPS to patients.  
The results show that IL15-DC have a more mature phenotype than IL4-DC. On the 
other hand, IL15-DC have a less mature phenotype than CYTO-DC.  
The results show that culturing monocytes for 5-6 days with GM-CSF and IL-15 led 
to their differentiation into cells that had the morphology and phenotypic properties of 
DC. After harvesting the IL15-DC, the cells were smaller in size than the IL4-DC.  
Monocyte-derived DC that are generated by adding GM-CSF and IL-4 are 
characterised by being CD14– CD1a+. CD14 is a monocyte/macrophage surface 
marker that is down-regulated upon differentiation of monocytes into DC. However, 
as shown in figure 4.2, all IL4-DC unexpectedly still expressed a relatively high 
amount of CD14. This could be attributed to non-specific binding of CD14 antibodies 
to Fc receptors. It could also be attributed to antibodies drying out, which could 
happen if a master mix of antibodies was not used. In my experiments, CD14 
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antibodies were the first antibodies to be pipetted to the wells. Other antibodies were 
then added one by one to the wells. So the probability of CD14 antibodies to be dry 
was high because of the time taken to add all other antibodies. The use of antibody 
master mix solved this particular problem, yet other problems still existed that were 
difficult to deal with because of time limitation. In figure 5.1 A, the CD14+ population 
in the IL4-DC looks as if it is caused by unspecific staining as both CD1a positive and 
CD1a negative cell populations have shifted towards being CD14+. Compared to that, 
a distinct CD14 positive CD1a negative population of the IL15-DC is shown in figure 
5.1 B.  
  
 
 
 
Figure 5.1 A distinct CD14+ cell population present in IL15-DC but not in IL4-DC. Monocytes 
were cultured with GM-CSF and IL-4 (IL4-DC) for 6 days. Monocytes were cultured with GM-CSF 
and IL-15 (IL15-DC) for 6 days. The figure shows a representative experiment of three experiments. 
Flow cytometry was used to determine the percentage of cells that expressed CD14 (X axis) and CD1a 
(Y axis). (A) Both CD1a positive and CD1a negative cell populations have shifted towards being 
CD14+ in the IL4-DC. (B) A distinct CD14 positive CD1a negative population is present in the IL15-
DC.  
 
 
Phenotypic analyses by flow cytometry showed that CYTO-DC expressed more 
HLA-DR, CD86, and CD83 than IL15-DC. However, the IL15-DC expressed more 
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maturation markers, i.e. HLA-DR, CD80, CD83, and CD86, than IL4-DC. The results 
show that the stimulated IL15-DC with TNF-α showed no difference from the non-
stimulated IL-15-DC in the expression of most of the surface markers except for the 
surface marker CD86 which was up-regulated. 
It is the mature DC and not the immature DC that can be utilized in vaccination 
against cancer. Taking this into consideration, it is very important that DC maturation 
markers are checked for their level of expression after DC are stimulated. Highly 
expressed maturation markers could be an indicator for a higher probability of good 
DC efficiency in T-cell activation. The co-stimulatory molecules CD80 and CD86 are 
responsible for delivering activation signals to the T-cells through the binding to 
CD28, the co-stimulatory receptor. This binding will deliver a potent co-stimulatory 
signal that leads to T-cell responses. These responses include the differentiation of 
naïve T-cells into effector and memory cells as well as production of cytokines such 
as IL-12. The CD83 molecule is another important DC maturation surface marker and 
it is thought that it plays an important role in the activation of certain immune 
responses (54).  
The results show that CD80 was higher expressed in the IL15-DC population than in 
the IL4-DC population, which is in line with a previous study (53). However, the 
same study also showed that CD86 was expressed more on IL4-DC than IL15-DC 
which is in contrast to our findings. In another study, IL15-DC showed a lower 
expression of CD80 and CD83, but a considerably high expression of CD86 (26). An 
explanation for the different results could be related to the use of different stimuli. In 
this study, the cytokine cocktail IL-6, TNF-α, IL-1β and PGE2 and TNF-α were used 
to stimulate IL4-DC and IL15-DC, respectively. In two previous studies, LPS was 
used to stimulate both IL4-DC and IL15-DC (26, 53). Other differences are that in the 
first study the monocytes were cultured for 3-4 days, i.e. less time than that used in 
this study, whereas in the second study, the lymphocytes and CD1a+ DC were 
depleted in order to get a pure monocyte population, i.e. a different purification 
protocol than that used in this study (26, 53).  
We speculated that the stimulation of IL15-DC with TNF-α might lead to the up-
regulation of the surface maturation markers. My results show, however, that CD80 
was down-regulated, CD83 was not changed, and CD86 was the only surface marker 
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that was up-regulated. Other studies showed that up-regulation of CD80, CD83 and 
CD86 occurred when IL15-DC were stimulated with LPS (26, 53).  
The results show that the IL15-DC expressed more HLA-DR, i.e. MHC class II than 
IL4-DC, but yet less than that of CYTO-DC. When we examined the median 
fluorescence intensity (MFI) of the four populations, we found that the MFI of the 
IL15-DC was higher than both IL4-DC and CYTO-DC. MHC class II molecules are 
very important as they present antigens to CD4+ T-cells. In the current study, all DC 
populations showed the same expression level of CD40 but when it comes to the MFI 
it was found to be higher in the IL15-DC than in both the IL4-DC and the CYTO-DC. 
CD40 molecules are expressed on DC and are up-regulated during the process of DC 
maturation. CD40 functions as a trigger for the expression of the co-stimulatory 
molecules which are required for efficient T-cell activation. In addition to, the CD40 
ligation of DC has the capacity also to induce high level of IL-12 secretion (55).  
The results show that CCR7 was expressed more on CYTO-DC and approximately 
equally on both IL4-DC and IL15-DC. CCR7 is one of the necessary chemokine 
receptors for DC migration. However, all the four DC populations were generally 
considered to have low expression of CCR7, which was confirmed by the chemotaxis 
assay result. The four DC populations did not show any migratory ability towards 
CCL19 (data not shown). It has been shown previously that the migration of skin DC 
toward the lymph nodes is impaired in CCR7-deficient mice under inflammatory 
conditions (56).  
The surface marker CD38 was also analysed. The results show that CD38 was down-
regulated on CYTO-DC while there were no detectable differences between the 
stimulated IL15-DC with TNF-α and the non-matured IL15-DC. A previous study 
showed that CD38 could regulate adaptive immunity by controlling the migration of 
DC and DC precursors (57). Moreover, another study showed that the CD38 could 
up-regulate CD83 expression and IL-12 secretion (58). However, this is in contrast to 
my result. In my study IL15-DC expressed a high level of CD38 but low level of 
CD83. Moreover, IL15-DC did not produce IL-12 (data not shown). The presence of 
IL-12 in the cell culture supernatants of all the DC populations was analysed. The 
results show that IL-12 was not detected in the supernatants of any of these 
populations. It has been shown before that DC produce various amount of IL-12 
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depending on the stimulus used (59). In this study, it was expected that CYTO-DC 
might not produce IL-12 as previously documented (59). The IL-12 production by 
IL15-DC was assessed for the first time in this study.  
The phosphorylation of three distinct mitogen-activated protein kinase (MAPK) 
signalling cascades, including the extracellular signal-regulated kinase (ERK), p38, 
and the c-Jun N-terminal kinase (JNK) pathways were analysed in all DC populations 
by Western blotting. The results show that even after 24 hours of incubation of DC for 
stimulation, which is a long time for phosphorylation signalling analysis, the P-JNK 
in the CYTO-DC and the P-ERK in the stimulated IL15-DC with TNF-α were 
detected. The analysis of the signalling pathways stimulation after a shorter period of 
incubation was not feasible in this study because of time limitations. The cells were 
stimulated for 24 hours in order to be able to do phenotypic analyses (FACS), 
chemotaxis assays and MLR. Several reports have shown that the activation of the 
three MAPK pathways occurs during DC maturation (60-62). However, the number 
of pathways activated depends on the stimuli (60-62). This is also shown in our result 
in which the CYTO-DC had the highest levels of P-JNK46/54. However, the CYTO-
DC had not the highest levels regarding P-ERK42/44 and P-p38 expression.  
The JNK and p38 pathways are activated by stress-inducing agents whereas the ERK 
signalling cascade regulates cell proliferation and differentiation in response to 
mitogens and growth factors (63). The results show that IL15-DC had similar levels 
of P-ERK42/44 and P-p38 as that of CYTO-DC. However, the CYTO-DC had the 
highest level of P-JNK46/54. The MAPK signalling pathway has a role in the 
maturation of DC. A recent study demonstrated that the blockage of the p38 MAPK 
pathway could inhibit the up-regulation of CD40, CD80, CD86, CD83, and HLA-DR 
(64). The inhibition of JNK also resulted in decreased expression of CD80, CD86, 
CD83 and increased expression of MHC class II on LPS stimulated DC (65). In a 
previous study, ERK pathway inhibitors increased the expression of MHC class II 
complex and co-stimulatory molecules (66). It is difficult to draw a conclusion out of 
my result since the signalling pathway analysis was done after 24 hours of DC 
stimulation which is not ideal.  Therefore, further analyses in the future should be 
performed.  
In order to analyse the T-cell stimulatory capacity of the different DC populations, a 
MLR was performed. The result shows that the lymphocytes that had been co-
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cultured with allogenic CYTO-DC showed the highest percentage of lymphocyte 
proliferation. On the other hand, lymphocytes that had been co-cultured with IL4-DC 
had a higher percentage of proliferation than cells co-cultured with both IL15-DC and 
the stimulated IL15-DC with TNF-α. As this data was based on only one experiment, 
it needs to be confirmed in the future.  
It is known that the maturation of DC is crucial for the initiation of T-cells, and from 
our results we can conclude that the CYTO-DC are the more efficient cells in T-cell 
stimulation compared to IL15-DC.  
The variation in the results of the three experiments presented in this thesis regarding 
the expression levels of DC surface markers and signalling pathway analysis might be 
explained simply by donor related variations. It could be also because uneven 
distribution of the cytokines between cells. This could be either during the 
replenishing of the cytokines during generation of DC or during addition of the 
stimulating cytokines. In other words it could be that not all cells had received enough 
cytokines. Another explanation could be that the monocyte population was originally 
contaminated with lymphocytes, which can affect the analyses outcome of the IL15-
DC. Furthermore, the variation in the surface marker levels of expression could be 
because of adding improper amount of surface marker antibodies or long incubation 
of DC with the surface marker antibodies.  
A total of 21 experiments were performed in this study. However, due to different 
reasons, only 3 experiments could be presented in the current thesis. For example, in 5 
experiments, few cells were obtained of which 2 of them had a lot of thrombocytes. 
Another 3 experiments were omitted because CYTO-DC had very low CD83 
expression and in 5 experiments, the IL15-DC were lost after harvesting. Two 
experiments were omitted because of low HLA-DR expression in CYTO-DC and 
very high CD14 expression in IL4-DC, respectively, indicating that the generation of 
this cell population had not been successful. Finally, 3 experiments were taken away 
for other reasons. 
Although it is known that monocytes strongly stick to the plastic, the loss of 
monocytes during the washing steps after adherence was one of the major problems.  
Several experiments were stopped because of the low amount of cells still in the 
flasks after washing. It was also observed that cells like thrombocytes adhered to the 
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plastic instead of monocytes which resulted in low numbers of monocytes. Monocyte 
isolation from PBMC by adherence is a common procedure. About 10% of PBMC are 
plastic-adherent monocytes. However, monocyte isolation by adherence can be 
associated with a high degree of contamination with lymphocytes (67). In this study, 
it was observed that lymphocyte contamination was one of the main problems during 
sample preparation in three experiments. It was thought that this could be because of 
improper wash of the monocytes, a critical step in order get red of the lymphocytes to 
start with a pure monocyte population.  
Loss of IL15-DC during cell harvesting was another obstacle. In three out of five 
experiments, IL15-DC were present in the flasks and looked as a nice DC population. 
The proper number of IL15-DC was obtained and their viability was checked. 
However, during the FSC/SSC analyses of the flow cytometry no IL15-DC population 
was present. One explanation could be that IL15-DC were sticking strongly to the 96-
well plate during the staining procedures preceding flow cytometry. It appears that 
IL15-DC were very sensitive and might be subjected to death if a short delay occurred. 
Some experimental procedures took longer time than we anticipated. For example, 
IL15-DC were very sticky to the flasks which, therefore, required more time to 
harvest. Thus, the IL15-DC were subjected to longer time of EDTA treatment to 
detach sticky cells. The EDTA is a chelating agent that can reduce cell viability if it 
stayed for too long.  
Adding IL-15 to monocytes that are contaminated with lymphocytes will lead to the 
stimulation and proliferation of T-cells. It was observed that there was a colour 
change of the cell culture medium of the IL15-DC population in some experiments 
which might be related to the stimulation and proliferation of T-cells.  
The technical problems in the experiments can be overcome in the future by using 
alternative techniques of monocyte isolation. One of these techniques can be the 
elutriation technique. In this technique, the PBMC are isolated first from whole blood 
by Ficoll gradient then the PBMC are separated by an elutriation procedure. 
Monocytes can also be isolated from PBMC by using CD14 magnetic beads. This 
method is simple and reliable and purity of up to 98% is reported (68). However, the 
method is expensive. In addition, this technique leads to the loss of the CD14–
monocyte population. Another way of monocyte isolation from PBMC is by depletion 
of lymphocytes, i.e. T-, B-, and NK-cells. This technique is easy to use and yields a 
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high purity of monocytes but is even more expensive than positive selection of CD14+ 
cells. The elutriation technique is the most suitable technique to be used in 
immunotherapy.  
 
5.1 Conclusions and future perspectives 
 
The generation of IL15-DC turned out to be more problematic compared to the 
generation of IL4-DC. The stimulatory activity of IL-15 on T-cell proliferation 
resulted in a high degree of contamination with T-cells in the IL15-DC cultures as we 
did not have a pure monocyte population to start with. This problem can in future be 
overcome by using either alternative monocyte isolation protocols or by reducing the 
culture period from 5-6 to 3-4 days. It might also be worth trying different stimuli to 
induce the maturation of IL15-DC as the use of TNF-α did not result in a remarkable 
stimulation. Moreover, due to the variation in the results between the experiments, my 
data needs to be confirmed with this approach. 
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